AstraZeneca is celebrating as the FDA announced the approval of its IL-5 inhibitor Fasenra (benralizumab) in a pre-filled, single-use auto-injector form, known as the Fasenra Pen.
The decision was based on Phase 1 and 3 data from two separate trials, and follows the product’s approval in the EU. Fasenra is currently approved in the US, EU, and Japan as an add-on treatment for eosinophilic asthma.
